

CIN no: L24234MH2005PLC158420

2nd February 2016

To,

Mr. Jeevan Noronha,

Manager - DSC

BSE Limited,

Floor 25, P J Towers,

Dalal Street, Mumbai – 400 001

Subject: Submission of Quarterly Audited Financial Results.

Dear Sir,

Attached herewith are the Quarterly Audited Financial Results of R J Bio-tech Limited for the Quarter ended 31st December 2015, considered and approved by the Board of Directors in their meeting held on 2nd February 2016.

Thanking You,


Yours Truly,

For R J BIO-TECH LIMITED



Mitesh Gadhiya

(Company Secretary)



ASHOK PATIL & ASSOCIATES
CHARTERED ACCOUNTANTS
A.P.Heights, Behind Gopal Cultural Hall, Osmanpura, Aurangabad.

INDEPENDENT AUDITOR'S REPORT

To,
The Board of Directors of
R J Bio-Tech Limited.


We have audited the quarterly financial results of **R J Bio-Tech Limited for the quarter Ended 31.12.2015**, and year to date results for the period 01.04.2015 to 31.12.2015, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard for Interim Financial Reporting (AS 25 / Ind AS 34), prescribed, under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder; or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.

In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results & year to date results

- (i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regard; and
- (ii) give true and fair view of the net profit and other financial information for the **quarter ended 31.12.2015** as well as the year to date results for the period from **01.04.2015 to 31.12.2015**.

For Ashok Patil & Associates
Chartered Accountants
Firm Reg. No. 122045W



(Ashok P. Patil)
Partner
M.No. 34423

Place : Aurangabad
Date: 02.02.2016

CIN no: L24234MH2005PLC158420


R J BIO-TECH LIMITED

CIN : L24234MH2005PLC158420

Statement of Audited Results for the Quarter and three months ended 31.12.2015

(Rs. in lakhs)

Sr. No.	Particulars	3 months ended 31.12.2015	Preceding 3 months ended 30.09.2015	Corresponding 3 months ended in the previous year 31.12.2014	Year to date figures for current period ended 31.12.2015	Year to date figures for the previous year ended 31.12.2014	Previous year ended 31.03.2015
01.	Income from Operations						
a.	Net Sales / Income From Operations	620.75	1,118.60	745.26	3241.05	2981.68	3166.83
b.	Other Operating Income	-	-	-	-	-	-
	Total Income from Operations	620.75	1,118.60	745.26	3,241.05	2981.68	3166.83
02.	Expenditure						
a.	Cost of Material Consumed	326.99	483.04	318.37	1517.75	1308.10	1026.79
b.	Purchase of Stock in Trade	-	-	-	-	-	-
c.	Change in Inventory of Finished Goods, Work in Progress and Stock in Trade	(122.44)	(70.06)	(61.71)	(285.75)	(210.55)	(212.45)
d.	Employee Benefit Expenses	44.28	48.01	55.06	148.62	179.07	252.56
e.	Depreciation and Amortization Expense	10.78	10.61	10.86	32.01	32.22	70.50
f.	Other Expenditure	163.57	243.56	272.69	997.43	1092.14	1523.47
	Total Expenses	423.18	715.16	595.27	2410.07	2400.98	2660.86
03.	Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	197.57	403.44	150.00	830.98	580.71	505.97
04.	Other Income	-	-	-	-	0.49	-
05.	Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 + 4)	197.57	403.44	150.00	830.98	581.20	505.97
06.	Finance Costs	82.11	85.02	87.47	250.04	261.00	359.54
07.	Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 + 6)	115.46	318.42	62.53	580.94	320.20	146.43
08.	Exceptional Items	-	-	-	-	-	-
09.	Profit / (Loss) from ordinary activities before tax (7 + 8)	115.46	318.42	62.53	580.94	320.20	146.43
10.	Tax expense	-	-	-	-	-	0.06
11.	Net Profit / (Loss) from ordinary activities after tax (9 + 10)	115.46	318.42	62.53	580.94	320.20	146.37



CIN no: L24234MH2005PLC158420

R J BIO-TECH LIMITED


CIN : L24234MH2005PLC158420

Statement of Audited Results for the Quarter and three months ended 31.12.2015

(Rs. in lakhs)

Sr. No.	Particulars	3 months ended 31.12.2015	Preceding 3 months ended 30.09.2015	Corresponding 3 months ended in the previous year 31.12.2014	Year to date figures for current period ended 31.12.2015	Year to date figures for the previous year ended 31.12.2014	Previous year ended 31.03.2015
12.	Extraordinary items	-	-	-	-	-	-
13.	Net Profit / (Loss) for the period (11 + 12)	115.46	318.42	62.53	580.94	320.20	146.37
14.	Paid-up equity share capital (Face Value of the Share shall be indicated)	946.76	946.76	946.76	946.76	946.76	946.76
15.	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	2004.25	1888.79	1608.68	2004.25	1608.68	1423.31
16 .i	Earnings Per Share (before extraordinary items)						
	Basic	1.22	3.36	0.66	6.14	3.38	1.55
	Diluted	1.22	3.36	0.66	6.14	3.38	1.55
16 .ii	Earnings Per Share (after extraordinary items)						
	Basic	1.22	3.36	0.66	6.14	3.38	1.55
	Diluted	1.22	3.36	0.66	6.14	3.38	1.55

Place: Aurangabad
Date: 02.02.2016



For R J Bio-Tech Limited

Raghendra Joshi

Raghendra Joshi
(Director)
DIN. 00307124

R J BIO-TECH LIMITED
CIN : L24234MH2005PLC158420

CIN no: L24234MH2005PLC158420


Audited Statement of Assets and Liabilities as on 31st December, 2015

(Rs. in Lakhs)

Particulars	As on 31-12-2015	As on 31-12-2014
I] EQUITY AND LIABILITIES		
(1) Shareholder's Funds		
(a) Share Capital	946.76	946.76
(b) Reserves & Surplus	2,004.25	1,608.68
(c) Money received against share warrants	-	-
(2) Share Application money pending allotment	-	-
(3) Non-Current Liabilities		
(a) Long-term Borrowings	256.47	236.03
(b) Deferred Tax Liabilities (Net)	-	-
(c) Other Long term Liabilities	110.01	109.85
(d) Long-term Provisions	-	-
(4) Current Liabilities		
(a) Short-Term Borrowings	2,465.88	2,058.57
(b) Trade Payables	300.45	361.52
(c) Other Current Liabilities	394.37	274.20
(d) Short-Term Provisions	65.90	38.64
TOTAL	6,544.09	5,634.25
II] ASSETS		
(1) Non Current Assets		
(a) Fixed Assets		
(i) Tangible Assets	218.84	284.55
(ii) Intangible Assets	0.10	0.16
(iii) Capital Work-in-progress	-	-
(iv) Intangible Assets under Development	-	-
(b) Non-Current Investments	-	-
(c) Deferred tax Assets (Net)	-	-
(d) Long-term loans & Advances	32.76	32.97
(e) Other non-Current assets	222.49	264.37
(2) Current Assets		
(a) Current Investments	-	-
(b) Inventories	2,689.95	2,576.74
(c) Trade Receivables	2,830.82	1,778.12
(d) Cash & Cash equivalents	34.64	11.63
(e) Short-term loans and advances	494.07	663.83
(f) Other current assets	20.43	21.88
TOTAL	6,544.09	5,634.25

Note:

- The Audited financial results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 02nd February, 2016.
- There were no Investor Complaints received / pending as on 31/12/2015.
- The Company does not have more than one reportable primary segment in terms of Accounting Standard 17 (AS 17 - Segment Reporting) issued by ICAI/Company (Accounting Standards) Rules, 2006. Therefore, the Company is not required to submit separate segment wise report.



For R J Bio-Tech Limited

Raghvendra Joshi
(Director)

DIN. 00307124

Place: Aurangabad
Date: 02.02.2016